Loading...
 
Toggle Health Problems and D

Digestive track Cancer (poorly differentiated) death 4X less likely if 2,000 IU of vitamin D – RCT Oct 2019

Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial.

Nutrients. 2019 Oct 22;11(10). pii: E2547. doi: 10.3390/nu11102547.
Yonaga H1,2, Okada S3, Akutsu T4, Ohdaira H5, Suzuki Y6, Urashima M7.

VitaminDWiki

Vitamin D Receptor and Cancers

Items in both categories Vitamin D Receptor and Cancer - Colon:

Items in both categories Vitamin D Receptor and  Cancer

Items in both categories Vitamin D Receptor and Cancer - other:

 Download the PDF from VitaminDWiki
Image

Image

Mainly Stomach Cancers
Image

Some coauthors of this study previously performed the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2,000 IU/day) in 417 patients with stage I to III digestive tract cancer from the esophagus to the rectum who underwent curative surgery (UMIN000001977).
We conducted a post-hoc analysis of the AMATERASU trial to explore the effects of modification of vitamin D supplementation by histopathological characteristics on survival. Among patients with poorly differentiated adenocarcinoma, the 5-year relapse-free survival rate of patients supplemented with vitamin D was 91% compared with 63% in the placebo group (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.08 to 0.78; P = 0.017; P for interaction = 0.023).
Similarly, the 5-year overall survival rate was 92% in the vitamin D group compared with 72% in the placebo group (HR, 0.25; 95%CI, 0.07 to 0.94; P = 0.040; P for interaction = 0.012).
In contrast, there were no significant effects in other histopathological characteristics between vitamin D and placebo groups. These findings generated the hypothesis that oral vitamin D supplementation may improve both relapse-free survival and overall survival in a subgroup of patients with poorly differentiated adenocarcinoma.


From the web

  • “The poorly differentiated neuroendocrine carcinoma subtype is characterized by its non-secretory, aggressive behavior and frequently grows in the gastrointestinal and genitourinary tracts [1]. The median survival of patients with this disease who have distant metastases is about five months.”
  • “As a rule, an undifferentiated cancer is more malignant than a cancer of that type which is well differentiated.”

Created by admin. Last Modification: Tuesday October 29, 2019 01:08:19 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
12877 mainly gastric.jpg admin 29 Oct, 2019 49.95 Kb 351
12876 Death poorly.jpg admin 29 Oct, 2019 46.40 Kb 453
12874 Digestive cancers.jpg admin 29 Oct, 2019 96.58 Kb 369
12873 Digestive tract cancer 2000 IU.pdf admin 29 Oct, 2019 1.37 Mb 415